

SUSTAINED GROWTH IN NET SALES FOR THE 1ST HALF OF 2016

Longjumeau, July 19, 2016

PCAS (Euronext Paris : PCA), a specialist in developing and producing complex molecules for life sciences and innovative technologies, has announced the publication of its consolidated net sales for the 1st half of 2016.

The PCAS Group's consolidated net sales totaled €100.7 million in the 1st half of 2016, 11.5% up on the same period in the previous financial year (+10.0% at a constant exchange rate).

<i>in millions of euros</i>	2016	2015	% change	2016 At a constant exchange rate	% change
Net sales at June 30	100.7	90.3	11.5%	99.3	10.0%
<i>Pharmaceutical Synthesis</i>	68.6	60.5	13.3%	67.3	11.2%
<i>Fine Specialty Chemicals</i>	32.1	29.8	7.9%	32.1	7.6%

Vincent Touraille, Chief Executive Officer of PCAS, explains: *"We are very satisfied with the direction in which our net sales have been heading at the end of the first half of the year. We can also confirm our sales growth targets, excluding growth through acquisition, both in Pharmaceutical Synthesis and in Fine Specialty Chemicals, and an increase in our results for 2016 as a whole, results for the 1st half of 2016 taking into account, as planned, the costs of the measures taken to optimize site organization in order to cope with a sustainable increase in the activity"*.

Pharmaceutical Synthesis

Pharmaceutical synthesis activities in Health generated €68.6 million, up 13.3% on 2015 (+11.2% at a constant exchange rate), particularly sustained by the Exclusive activity.

Fine specialty chemicals

Net sales of Fine Specialty Chemicals totaled €32.1 million, up 7.9% on 2015 (+7.6% at a constant exchange rate), this activity growing both in Performance Additives and Advanced Specialty Chemicals.



NEXT FINANCIAL DISCLOSURE:

1st half 2016 earnings report, September 7, 2016

About PCAS

PCAS specialises in the development and production of complex molecules for Life Sciences and Innovative Technologies. With 7% of its turnover dedicated to R&D and a wide international presence, PCAS is the preferred industrial partner of market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments, and also includes two subsidiaries with very strong potential: Protéus in biotechnology and Enersens in high-performance insulation. With a particularly high standard of performance, PCAS achieved net sales of €179.1 million in 2015 and employs nearly 900 people in six countries.

For more information about PCAS: www.pcas.com



PCAS

Vincent Touraille / Eric Moissenot
PCAS

Tél. : +33 1 69 79 61 32
www.pcas.com

NewCap

Emmanuel Huynh / Louis-Victor Delouvrier
NewCap
Financial Communication & investors relations

Tél. : +33 1 44 71 98 53
pcas@newcap.eu